drugset / Trial / NCT01385228
Pazopanib, Docetaxel, Prednisone Prostate
RandomizedSingle-groupOpen-labelTreatment
Summary
The primary purpose is to define the safety and tolerability of docetaxel/prednisone in combination with pazopanib (DPP) in men with metastatic Castration Resistant Prostate Cancer (mCRPC).
Timeline
- Start
- 2011-06
- Primary completion
- 2015-07
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Pazopanib | Small molecule | 400 mg | Oral |
| Subject | Pazopanib | Small molecule | 600 mg | Oral |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |
| Subject | Pazopanib | Small molecule | 1000 mg | Oral |
| Background | Pegfilgrastim | Protein / enzyme biologic | — | — |
| Background | Prednisone | Other / unclassified | 5 mg | — |